CLIMB BIO INC (CLYM:NASDAQ)
$9.17 0.35 (3.9683%)
Analysed CLIMB BIO INC (CLYM:NASDAQ) News Sources
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
08-04-2026
yahoo.com
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
07-04-2026
yahoo.com
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
06-04-2026
yahoo.com
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026
14-03-2026
marketbeat.com
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
05-03-2026
yahoo.com
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference
26-02-2026
marketbeat.com
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit
13-02-2026
marketbeat.com
Climb Bio to Present at Upcoming Investor Conferences
05-02-2026
yahoo.com
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate
24-01-2026
yahoo.com
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
08-01-2026
yahoo.com
What is the current price of CLIMB BIO INC (CLYM:NASDAQ)?
The current price of CLIMB BIO INC (CLYM:NASDAQ) is $9.17.
CLIMB BIO INC (CLYM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is $0.35.
CLIMB BIO INC (CLYM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is 3.9683%.
What is the most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent sentiment for CLIMB BIO INC (CLYM:NASDAQ) is .
SEC-8K** Filing Available For CLIMB BIO INC (CLYM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.